Reducing the symptom of psoriasis through decreasing the levels of pro-inflammatory cytokines including IL-17A, IFN-γ, IL-6, and TNF-α and Th17 cells. Increasing the population of Th2 cells in both spleen and skin. The gene discussed is IFNG; the disease is psoriasis.